- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02661035
Allo HSCT Using RIC for Hematological Diseases
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32]
Study Overview
Status
Conditions
- Follicular Lymphoma
- Myelodysplastic Syndromes
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
- Lymphoblastic Lymphoma
- Chronic Lymphocytic Leukemia
- Lymphoplasmacytic Lymphoma
- Acute Lymphocytic Leukemia
- Acute Myelogenous Leukemia
- Mantle-Cell Lymphoma
- Chronic Myelogenous Leukemia
- Prolymphocytic Leukemia
- B-Cell Lymphoma
- Hematological Diseases
- Plasma Cell Leukemia
- Small Lymphocytic Lymphoma
- Burkitt's Lymphoma
- Myeloproliferative Syndromes
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Masonic Cancer Center at University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Age, Performance Status, and Graft Criteria
- Age 0 to 70 years of age with Karnofsky score ≥ 70% (≥ 16 years) or Lansky score ≥ 50 (< 16 years)
- Patients ≥ 70 and ≤ 75 years of age may be eligible if they have a HCT-CI Co-Morbidity score ≤ 2
- Must be ≥ 3 months after prior myeloablative transplant, if applicable
- 5/6 or 6/6 related donor match or a 7-8/8 HLA-A,B,C,DRB1 allele matched unrelated donor marrow and/or PBSC donor match per current institutional guidelines Related donors will be evaluated and collected per MT2012-14C; Unrelated donors will be identified and collected per usual procedures
Eligible Diseases
- Acute Myeloid Leukemia (AML): high risk CR1 (as evidenced by preceding MDS, high risk cytogenetics, ≥ 2 cycles to obtain CR, erythroblastic or megakaryocytic leukemia, FLT-3 ITD +; CR2+. All patients must be in CR as defined by hematological recovery, AND <5% blasts by light microscopy within the bone marrow with a cellularity of ≥15%.
- Very high risk pediatric patients with AML: Patients <21 years, however, are eligible with (M2 marrow) with < 25% blasts in marrow after having failed one or more cycles of chemotherapy.
- Acute Lymphocytic Leukemia (ALL): factor that define high risk CR1 include but are not limited to cytogenetics demonstrating t(9;22), t (1:19), t(4;11), other MLL rearrangements, hypodiploidy, or IKZF1 abnormalities), DNA index < 0.81, > 1 cycle to obtain CR or presence minimal residual disease (MRD). Patients in CR2+ are eligible. All patients must be in CR as defined by hematological recovery, AND <5% blasts by light microscopy within the bone marrow with a cellularity of ≥15%.
- Very high risk pediatric patients with ALL: patients <21 years are also considered high risk CR1 if they had M2 or M3 marrow at day 42 from the initiation of induction or M3 marrow at the end of induction. They are eligible once they achieved a complete remission.
- Chronic Myelogenous Leukemia excluding refractory blast crisis: To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to imatinib mesylate.
- Plasma Cell Leukemia after initial therapy, who achieved at least a partial remission
- Myelodysplasia (MDS) requiring transplant as defined as: IPSS INT-2 or High Risk; R-IPSS High or Very High; WHO classification: RAEB-1, RAEB-2; Severe Cytopenias: ANC < 0.8, Anemia or thrombocytopenia requiring transfusion; Poor or very poor risk cytogenetics based on IPSS or R-IPSS definitions; therapy-related MDS. Blasts must be < 5% by bone marrow aspirate morphology.
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone B-Cell Lymphoma or Follicular Lymphoma are eligible if there was disease progression/relapse within 12 of achieving a partial or complete remission. Patients who had remissions lasting > 12 months, are eligible after at least two prior therapies. Patients with bulky disease (nodal mass greater than 5 cm) should be considered for de-bulking chemotherapy before transplant.
- Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, NK cell malignancies are eligible after initial therapy in CR1+ or PR1+.
- Large Cell NHL > CR2/> PR2: Patients in CR2/PR2 with initial short remission (<6 months) are eligible.
- Lymphoblastic Lymphoma, Burkitt's Lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 year.
- Multiple Myeloma beyond PR2: Patients with chromosome 13 abnormalities, first response lasting less than 6 months, or β-2 microglobulin > 3 mg/L, may be considered for this protocol after initial therapy.
- Myeloproliferative Syndromes
Organ Function Criteria Adequate organ function is defined as:
- Liver: AST and ALT < 5 x upper limit of normal and bilirubin < 3 x upper limit of normal
- Renal: Creatinine ≤ 2.0 mg/dl (adults) and estimated glomerular filtration rate (GFR) ≥ 40 mL/min (pediatrics). Adults with a creatinine > 1.2 mg/dl or a history of renal dysfunction must have estimated glomerular filtration rate (GFR) > 40 mL/min.
- Albumin > 2.5 g/dL
- Cardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 35%.
- Pulmonary: DLCOcorr ≥ 40% predicted, and absence of O2 requirements. For children that are not able to cooperate with PFTs, a pulse oximetry with or without exercise should be attempted. If neither test can be obtained it should be clearly stated in the physician's note.
- If recent mold infection (e.g. aspergillus) must have minimum of 30 days of therapy and responsive disease and be cleared by Infectious Disease
- Females of child bearing potential and sexually active males must agree to use adequate birth control during study treatment
- Voluntary written consent (adult or parent/guardian with presentation of the minor information sheet, if appropriate)
Exclusion Criteria:
- Pregnant or breast feeding. The agents used in this study include Pregnancy Category D: known to cause harm to a fetus. Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy.
- Untreated active infection
- Active CNS disease
- Active HIV infection or known HIV positive serology
- Congenital bone marrow failure syndrome
- Previous irradiation that precludes the safe administration of an additional dose of 200 cGy of TBI
- CML in refractory blast crisis
- Intermediate or high grade NHL, mantle cell NHL, and Hodgkin disease that is progressive on salvage therapy. Stable disease is acceptable to move forward provided it is non-bulky.
- Multiple myeloma progressive on salvage chemotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Reduced Intensity Conditioning
Non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion
|
300 mg/day (for peds -150 mg/m^2/day), day -6 and continue through day 0 or longer if clinically indicated
Other Names:
30 mg/m^2 IV over 1 hour, day -6, -5, -4, -3 and -2
Other Names:
50 mg/kg IV over 2 hours, day -6
Other Names:
Only for patients with an unrelated donor (URD) and NO multi-agent chemotherapy 3 months prior to transplant.
ATG will be administered IV every 12 hours for 6 doses on days -6, -5, and -4 according to institutional guidelines.
Methylprednisolone 1 mg/kg IV administered immediately prior to each dose of ATG (6 doses).
Other Names:
All patients who have had previous radiation therapy or TBI will be seen by Radiation Oncology prior to entrance on the protocol for approval for additional 200 cGy of TBI.
TBI may be delivered by local guidelines provided the effective dose is equivalent to what is recommended in the TBI Guidelines.
The dose of TBI will be 200 cGy given in a single fraction on day -1.
Other Names:
All patients will receive tacrolimus therapy beginning on day -3. Initial dosing of tacrolimus will be 0.03 - 0.05 mg/kg/day IV; if the recipient body weight is <40 kg, dosing will be 3 times daily, and if ≥ 40 kg, twice daily or per current institutional guidelines. An attempt will be made to maintain a trough level of 5-10 ng/mL and subsequent dose modifications will be provided by the pharmacist. Once the patient can tolerate oral medications and has a reasonable oral intake, tacrolimus will be converted to an oral form based on the current IV dose providing normal renal and hepatic function and no major drug interactions. The timing of the tacrolimus taper will be at the discretion of the treating physician, but in general:
Other Names:
3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies. MMF will stop at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC) ≥ 0.5 x 109 /L]). If no donor engraftment, MMF will continue as long as clinically indicated.
Other Names:
On day 0, patients will receive an allogeneic transplant using PBSC which are CD34+ selected as the donor graft.
The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
On day 0, a target dose of 3 x 10^8 nucleated cells/kg recipient weight will be collected.
The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate rates of acute graft-versus-host disease (GVHD) II-IV
Time Frame: Day 100 post transplant
|
Percent of subjects with grade II-IV acute GVHD
|
Day 100 post transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate rates of chronic GVHD
Time Frame: 1 year post transplant
|
Percent of subjects with chronic GVHD
|
1 year post transplant
|
Evaluate neutrophil engraftment without ATG (in siblings)
Time Frame: Day 42 post transplant
|
Percent of subjects with neutrophil engraftment without ATG (in siblings)
|
Day 42 post transplant
|
Evaluate neutrophil engraftment with ATG (in unrelated donors)
Time Frame: Day 42 post transplant
|
Percent of subjects with neutrophil engraftment with ATG (in unrelated donors)
|
Day 42 post transplant
|
Evaluate neutrophil engraftment without ATG (in unrelated donors)
Time Frame: Day 42 post transplant
|
Percent of subjects with neutrophil engraftment without ATG (in unrelated donors)
|
Day 42 post transplant
|
Evaluate relapse without ATG (in siblings) - 1 year
Time Frame: 1 year post transplant
|
Percent of subjects who relapsed without ATG (in siblings)
|
1 year post transplant
|
Evaluate relapse without ATG (in siblings) - 2 years
Time Frame: 2 years post transplant
|
Percent of subjects who relapsed without ATG (in siblings)
|
2 years post transplant
|
Evaluate relapse with ATG (in unrelated donors) - 1 year
Time Frame: 1 year post transplant
|
Percent of subjects who relapsed with ATG (in unrelated donors)
|
1 year post transplant
|
Evaluate relapse with ATG (in unrelated donors) - 2 years
Time Frame: 2 years post transplant
|
Percent of subjects who relapsed with ATG (in unrelated donors)
|
2 years post transplant
|
Evaluate relapse without ATG (in unrelated donors) - 1 year
Time Frame: 1 year post transplant
|
Percent of subjects who relapsed without ATG (in unrelated donors)
|
1 year post transplant
|
Evaluate relapse without ATG (in unrelated donors) - 2 years
Time Frame: 2 years post transplant
|
Percent of subjects who relapsed without ATG (in unrelated donors)
|
2 years post transplant
|
Overall survival
Time Frame: Day 100 post transplant
|
Percent of surviving subjects
|
Day 100 post transplant
|
Overall survival
Time Frame: 1 year post transplant
|
Percent of surviving subjects
|
1 year post transplant
|
Overall survival
Time Frame: 3 years post transplant
|
Percent of surviving subjects
|
3 years post transplant
|
Transplant related mortality (TRM)
Time Frame: Day 100 post transplant
|
Percent of subjects with TRM
|
Day 100 post transplant
|
Transplant related mortality (TRM)
Time Frame: 1 year post transplant
|
Percent of subjects with TRM
|
1 year post transplant
|
Collaborators and Investigators
Investigators
- Principal Investigator: Erica Warlick, MD, Masonic Cancer Center, University of Minnesota
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Virus Diseases
- Infections
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Disease Attributes
- Disease
- Bone Marrow Diseases
- Hemorrhagic Disorders
- Myeloproliferative Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- DNA Virus Infections
- Tumor Virus Infections
- Neoplasms, Plasma Cell
- Epstein-Barr Virus Infections
- Herpesviridae Infections
- Leukemia, B-Cell
- Lymphoma, B-Cell
- Chronic Disease
- Lymphoma
- Syndrome
- Myelodysplastic Syndromes
- Multiple Myeloma
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Hematologic Diseases
- Burkitt Lymphoma
- Lymphoma, Mantle-Cell
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Waldenstrom Macroglobulinemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Prolymphocytic
- Leukemia, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antioxidants
- Antitubercular Agents
- Free Radical Scavengers
- Gout Suppressants
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Cyclophosphamide
- Fludarabine
- Tacrolimus
- Mycophenolic Acid
- Allopurinol
- Antilymphocyte Serum
Other Study ID Numbers
- 2015LS152
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Follicular Lymphoma
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; Pharmacyclics LLC.TerminatedFollicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIaUnited States
-
Olivia Newton-John Cancer Research InstituteBristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaboratorsRecruitingFollicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IVAustralia
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGrade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...United States
Clinical Trials on Allopurinol
-
Ardea Biosciences, Inc.Completed
-
Urica Therapeutics Inc.RecruitingHyperuricemia | GoutUnited States
-
Ardea Biosciences, Inc.Quotient ClinicalCompleted
-
AstraZenecaParexelCompletedChronic Kidney DiseaseGermany
-
Universita di VeronaCompletedChronic Heart FailureItaly
-
Ardea Biosciences, Inc.Completed
-
University of DundeeCompleted
-
Ardea Biosciences, Inc.Completed
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Failure | Elevated Serum Uric AcidUnited States, Canada